Cipla and Ethris partner for the development of mRNA-based therapies

Indian drugmaker Cipla Limited (BSE: 500087), via its UK subsidiary, has signed definitive agreements for an equity investment of 15 million euros ($16 million) in German biotech Ethris GmbH.

The investment will facilitate a long-term strategic partnership between Cipla and Ethris for the development of messenger RNA (mRNA)-based therapies and fast-track Cipla’s participation in the mRNA space, enabling it to provide access to cutting-edge solutions developed by Ethris for the developing countries.

A collaboration agreement is signed concurrently with the definitive agreement, which paves a path to market Ethris’ innovative portfolio in Cipla’s key emerging markets. The transaction is expected to complete within 60 days from the date of signing of the agreement or such other time-period as may be mutually agreed between the parties in writing and shall be subject to completion of necessary regulatory formalities.